VIGORous Debate Continues In NEJM Over Propriety Of Merck’s Vioxx Study
Merck's Vioxx VIGOR trial results do not need to be corrected, authors of the study assert in letters to the editors of the New England Journal of Medicine Feb. 22
You may also be interested in...
Medical journals need to take measures to expedite providing up-to-date information to physicians, FDA Deputy Commissioner for Scientific & Regulatory Affairs Scott Gottlieb said
The New England Journal of Medicine has asked the authors of a major Vioxx study to submit a correction restating results after the journal concluded that cardiovascular events were misrepresented in the study manuscript and that Merck had known about additional events prior to the trial's publication
Following Merck's decision to withdraw Vioxx from the market, an FDA approval of the follow-on COX-2 inhibitor Arcoxia is likely to be delayed